



## The effects of pentoxifylline administration on fracture healing in a postmenopausal osteoporotic rat model

Mohammad Mahdi Vashghani Farahani<sup>1</sup>, Reza Ahadi<sup>2</sup>,  
Mohammadamin Abdollahifar<sup>3</sup>, Mohammad Bayat<sup>4,\*</sup>

<sup>1</sup>Basic Sciences Department, Paramedical School, Shahid Beheshti University of Medical Sciences, Tehran, Iran

<sup>2</sup>Department of Anatomy, School of medicine, Iran University of Medical Sciences, Tehran, Iran

<sup>3</sup>Department of Anatomical sciences and Biology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

<sup>4</sup>Cellular and Molecular Biology Research Centre, Department of Anatomical Sciences and Biology, Medical School, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Previous studies report positive effects of pentoxifylline (PTX) alone or in combination with other drugs on some pathologic bone diseases as well as an ability to accelerate osteogenesis and fracture healing in both animal models and human patients. The aim of this present study was to evaluate the effects of PTX administration on Hounsfield unit and bone strength at catabolic response (bone resorbing) of a fracture in an experimental rat model of ovariectomy induced osteoporosis (OVX-D). Thirty adult female rats were divided into groups as follows: 1 (OVX, control, no treatment); 2 (OVX, sham: daily distilled water); 3 (OVX, daily alendronate: 3 mg/kg); 4 (OVX, twice daily 100 mg/kg PTX) and 5 (OVX, PTX+alendronate). OVX was induced by bilateral ovariectomy in all rats. A complete standardized osteotomy of the right femur was made after 3.5 months. PTX and alendronate treatments were performed for eight weeks. Then, rats were euthanized and had its right femur subjected to computerized tomography scanning for measuring Hounsfield unit; eventually, the samples were sent for a three point bending test for evaluation of the bone strength. Administration of PTX with 200 mg/kg and alendronate alone and in combination showed no significant alteration in Hounsfield unit and biomechanical properties of repairing callus of the complete osteotomy compared with the control group. Results showed increased bending stiffness and stress high load mean values of repairing complete osteotomy in PTX-treated rats compared to the control OVX-D.

**Keywords:** Osteoporosis, osteotomy, ovariectomy, femur, hounsfield unit biomechanical phenomena, rat

Received 12 December 2016; Revised version received 6 March 2017; Accepted 7 March 2017

Surgical conditions account for a significant portion of health problems worldwide and have a substantial impact on public health in low and middle-income countries [1]. Musculoskeletal injury causes disability and suffering and places a heavy burden on society, so such cases are a major source of surgical procedures thus a major concern in public health, globally [2]. This burden on could be considerably lessened by implementation of an affordable and sustainable strategy to accelerate healing in osteotomies and fractures [2]. Osteoporosis (OP) is a disease of the

bone common in middle-aged, post-menopausal women. Osteoporotic bones become weak and prone to fracture [3]. In the year 2000, there were an estimated 9.0 million osteoporotic fractures, of which 1.6 million were of the hip; 1.7 million forearm and 1.4 million were clinical vertebral fractures [4]. In 1995, the cost of osteoporotic fractures in the United States in 1995 was estimated at \$13.8 billion [5]. The consequences of osteoporotic fracturing include re-fracture, excess mortality and morbidity among patients and burdensome economic cost for the

\*Corresponding author: Mohammad Bayat, Cellular and Molecular Biology Research Centre, Shahid Beheshti University of Medical Sciences, Tehran 1985717443, Iran  
Tel: +1-312-605-6777; Fax: +1-312-942-5744; E-mail: bayat\_m@yahoo.com, mohbayat@sbm.ac.ir

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

healthcare system [6]. Causes of post-menopausal OP are thought to be multifactorial [7]; however, it is thought that basic pathological events in any type of OP involve an imbalance between bone resorption and formation due to an increase working lifespan or number of osteoclasts and a decline of the working lifespan or numbers of osteoblasts [8]. In postmenopausal OP, estrogen deficiency is thought to promote production of bone-resorbing hormones and cytokines (interleukin-1 [IL-1]), tumor necrosis factor- $\alpha$  [TNF- $\alpha$ ], IL-6) with osteoclastogenic action [9]. Conversely, it seems that agents that suppress production of these cytokines could prove helpful in preventing bone loss in postmenopausal OP. In theory, improved bone formation might induce a more adequate recovery of bone mass in osteoporotic patients [10]. This indicates the need to identify agents with osteogenetic potential in order to improve therapeutic efficacy in osteoporotic [10]. A number of *in vitro* studies have demonstrated that in osteoblastic cells, elevated levels of intracellular cyclic (adenosine monophosphate) AMP develop bone-forming activity [11,12]. This is consistent with research reported in Wronsky *et al.*, in that cyclic AMP and cyclic AMP-dependent protein kinase may be the most important initiators of growth response to intermittent pulse of parathyroid hormone (PTH) in rat bone [13]. In addition to the rate of synthesis of cAMP by adenylate cyclase, cAMP levels can be regulated by the rate of hydrolysis to the inactive form of 5' AMP by cyclic nucleotide phosphodiesterases (PDEs). So PDE enzymes degrade intracellular cAMP [14, 15]. General or non-selective phosphodiesterase inhibitors (1-(5-oxohexyl)-3,7-dimethylxanthine or Pentoxifylline, (PTX)) are effective in elevating intracellular c-AMP levels by inhibiting the breakdown of c-AMP by PDEs [10]. PTX was originally used as a hemorrheologic drug to treat intermittent claudication, with minor side effects [16]. Previous studies report positive effects of PTX alone or in combination with other drugs on some pathologic bone diseases including osteoradionecrosis, arthritis; as well as an ability to accelerate osteogenesis and fracture healing in both animal models and human patients [17-27]. However, only a few studies have elucidated the effects of PTX on osteoporotic cells *in vitro* or in cases of corticosteroid-induced OP. Robin and Ambrus cultured osteoblast-like cells from calvariae of rats. Tests determined that PTX increased cAMP levels and calcium uptake in these cultures [28]. Robin and

Ambrus, reports induced OP in C3H/St (Ha) of female mice after 3 months of treatment by heparin *in vitro*. Tests determined that PTX prevented OP and increased calcium uptake and cAMP production in osteoblast-like bone cells isolated from fetal rats [29]. Magremanne and Reychler report affirmation that osteonecrosis of the jaw (ONJ) as an important side effect of bisphosphonate (BP) therapy but that was also presented ONJ development after zoledronic acid infusions (3 yearly) for corticosteroid-induced OP. Treatment was successfully managed using conservative treatment with PTX and tocopherol [30]. Recently Takami *et al.*, illustrated that PTX stimulated osteoclast formation in cocultures of mouse bone marrow cells and calvarial osteoblasts. PTX induced expression of osteoclast differentiation factor, TNF-related activation induced cytokine (TRANCE), identical to receptor activator of nuclear factor kappa-B ligand or (RANKL), osteoclastogenesis-inhibitory factor (ODF), and Osteoprotegerin (OPGL)), in calvarial osteoblasts [31].

Alendronate sodium is a nitrogen-containing oral bisphosphonate used for the treatment of osteoporosis [32]. Approximately 50% of patients treated with alendronate show a decrease in the incidence of osteoporotic fractures in the hips and spine as a result of improved bone density and reduced bone resorption. Alendronate makes a continuous decrease in the points of biochemical markers of bone remodeling, recurring them to the premenopausal range. It also increases bone mineral density and declines the risk of osteoporotic fracture in postmenopausal females. Longstanding intervention investigations have revealed that continuous alendronate administration is associated with a sustained therapeutic effect on bone density and remodeling [33].

Latest progresses in imaging technologies for example computerized tomography (CT) scanning have made it possible to evaluate the healing process of the bones by measuring the Hounsfield unit (HU) of bone tissue [34,35].

This study aimed to evaluate the effects of PTX administration with 200 mg/kg (which was administered successfully on fracture healing in healthy rats in previous studies [17,25] on Hounsfield unit and biomechanical parameters of callus of complete osteotomy of femur in an experimental rat model of ovariectomy induced OP (OVX-D). The remodeling phase of fracture healing (catabolic phase) was evaluated with Hounsfield unit and a biomechanical test [36].


## Materials and Methods

### Animals and study design

Thirty adult female Wistar rats, 5 months old and weighing about 240 g, were used. Rats were provided with food and water ad libitum and were weighed weekly throughout the study duration. Rats were divided into groups 1 (OVX, control: no treatment); 2 (OVX, sham: daily distilled water, intraperitoneal, IP); 3 (OVX, daily alendronate: 3 mg/kg, subcutaneous, SC, Alborz Darou, Tehran Co, Iran); 4 (OVX, daily PTX: Sigma-Aldrich, St. Louis, MO, USA, IP, 100 mg/kg at 9 a.m. and 100 mg/kg 5 p.m.) and 5 (OVX, PTX+alendronate). OVX was induced in all rats. A complete standardized osteotomy of right femur was made after 3.5 months. PTX and alendronate treatments were performed for eight weeks. Then, rats were euthanized and the right femur of each rat was submitted to CT scanning and a three point bending test to evaluate callus density and strength of the repaired bone. All procedures were approved by the Medical Ethics Committee at Shahid Beheshti University of Medical Sciences, Tehran, Iran (protocol no 1392-1-115-1159).

### Ovariectomy

All rats were subjected to total OVX. OVX was carried out on two paravertebral skin incisions while rats were under sterile conditions and general anesthesia. On the day of surgery (day zero), each rat was anesthetized with an intramuscular injection of ketamine (50 mg/kg) and diazepam (5 mg/kg) for relief of postoperative pain rats received 20 mg/kg Ibuprofen (Emaddarmanpars Co, Tehran, Iran) preoperatively and then every 8 to 12 hours for the next 5 days after surgery [37]. The skin of each rat was shaved and sterilized with several scrubs of povidone iodine (betadine) and 50% ethanol. Uterine tubes were ligated and incisions were closed following removal of ovaries (Figure 1) [36]. Antibiotic therapy with Ceftriaxone (Jaber ben Hayan Co, Tehran, Iran) at a dose of 50 mg/kg was injected intramuscularly into the rats immediately before surgery and then 24 and 48 h after surgery. All animals were kept for 3.5 months after surgery in cages in order to develop OP [31,38]. At the end of this period, rats were submitted to CT scanning to establish OP. Rats were then subjected to complete osteotomy in the right femur.




**Figure 1.** Steps in ovariectomy. The images show the incision (A), exposing ovary (B), Removing ovary and suturing abdominal end of ovarian tube (C), Suturing abdominal wall and skin incision (D).

### CT scanning

OP development of OVX-D and callus densities was evaluated qualitatively by CT using multislices (kV=100, ma=50, sections=2 mm, FOV=240 mm, Toshiba, Aquilion 16, Japan) when compared with healthy rats. Evaluation of femoral bone density of osteoporotic rats was determined under general anesthesia. Moreover 2 months after OVX callus densities of all rats were evaluated by the CT scanning. Callus densities of bone defects were determined immediately after euthanizing. All tests were performed by an expert radiologist and bone density evaluations were recorded in Hounsfield Units (HU) [34]. The radiologist was unaware of the group divisions.

### Femoral fracture model (surgical standard complete transverse osteotomy)

Each rat was anesthetized, had its skin sterilized and antibiotic therapy was performed as mentioned before. One incision (1-cm) was made over the lateral aspect of the right thigh to expose the femur. The first step was to make three to five partial transversal standardized osteotomies, circular deep to the central medullary canal at midpoint of the femur. These were made with a low speed drill (terminal, 1.0-mm diameter) (Delab; Dental Fabriktreffurt, Germany), then the osteotomy site was broken manually and bones were divided into two parts. During osteotomy bones were irrigated with saline solution to avoid burning. Intramedullary fixation was




**Figure 2.** Different steps of complete osteotomy operation. The image shows the incision (A), exposed femur's mid shaft (B), circular partial transverse standardized osteotomies procedure with low speed drill (C), complete fracture in the bone (D), inserting a stainless wire (E). Reduction was maintained with the stainless wire (F)

performed using stainless wire (diameter, 1.0 mm). Fracture fragments were contacted and stabilized. A distance of 3 mm (gap) was maintained between the edges of fractures, constant in the entire population of rats. Wires were cut on the surface of the femur's intercondylar groove to avoid restricted motion in the knee joint. Muscle tissue was sutured with 04 catgut (Supa, Iran) and skin was sutured with 04 nylon reversed cutting sutures (Figure 2). Unrestricted activity was allowed after recovery from anesthetic [17].

### Biomechanical examination

Eight weeks after surgery, all rats were anesthetized in the same way as before. During anesthesia, rats were euthanized via an intracardiac dose (200 mg/kg) of pentobarbital sodium and benzyl alcohol (Dolethal). Right femurs were collected. Biomechanical properties of six bones in each group were examined. Bones were submitted to three-point bending on a material testing device (Zwick/ Roell Group Z 2.5 H 15WN, UIm, Germany) until fracture occurred. All bones were oriented similarly in the testing machine. Two loading



**Figure 3.** Mean±SD of Hounsfield unit in the groups compared by the ANOVA and LSD tests. Groups: 1 (OVX, control), 2 (OVX, Sham), 3 (OVX, alendronate), 4 (OVX, PTX), and 5 (OVX, PTX and alendronate).

bars, 19 mm apart were used to mount each bone, and a mobile head was activated to compress the midline of the bone shaft until fracture occurred. The compressive loading speed in the test was 0.08mm/s. Data were automatically recorded by the material testing device from the load-deformation curve and the following values were calculated: bending stiffness (N/mm), maximum force (N), high stress load (N/mm<sup>2</sup>), and energy absorption (N mm)[17].

### Statistical analysis

All data were expressed as mean±standard deviation. Normal distribution of data were analyzed using one sample Kolmogorov-Smirnov test. Differences between treatment groups were tested by one-way analysis of variance (ANOVA). If significant difference was indicated, then difference between the two groups was tested by Least Significant Difference (LSD). First body weight of rats and their last body weights, and Hounsfield units of OVX-D and healthy control groups were analyzed using the student t test. The *P* value of <0.05 was considered statistically significant.

## Results


### General observations

There were no adverse effects such as oral hemorrhage, vomiting, diarrhea or dysentery were observed in any of the rats. A total of 7 rats were excluded due to poor fracture healing (non-union) or death after surgery. These 7 rats were replaced. Rats in the alendronate and


**Table 1.** Mean±SD of first body weight(g) and last body weight of study groups

PTX+Alen	PTX	Alen.	Sham	Control	Groups	
					Body weight	
248.29±25.04	214.60±19.84	258.83±26.51	231.83±27.26	241.60±11.76	First	
246.00±23.68*	214.60±17.27	255.83±23.04*	233.17±27.74	246.80±8.32	Last	

Paired student t test showed there were significant decreases in body weights of alendronate(alen.) and alen.+PTX groups;  $*=P<0.05$



**Figure 4.** Mean±SD of bending stiffness in the groups compared by the ANOVA and LSD tests. Groups: 1 (OVX, control), 2 (OVX, Sham), 3 (OVX, alendronate), 4 (OVX, PTX), and 5 (OVX, PTX and alendronate).



**Figure 5.** Mean±SD of maximum force in the groups compared by the ANOVA and LSD tests. Groups: 1 (OVX, control), 2 (OVX, Sham), 3 (OVX, alendronate), 4 (OVX, PTX), and 5 (OVX, PTX and alendronate).

alendronate+PTX groups showed a significant decrease in body weight at the end of the study (Table 1).


### Hounsfield units analysis

Student t test analysis revealed a significant decrease in femoral bone density of OVX-D ( $635.8 \pm 24.36$  HU) compared with the control (healthy group) ( $787.8 \pm 24.8$  HU), ( $P=0.000$ ).

PTX-treated rats showed significant decrease in Hounsfield unit compared to alendronate, and alendronate +PTX groups (LSD test, both  $P=0.000$ ). There were significant decrease in Hounsfield unit of PTX, sham, and alendronate groups compared to control group (LSD test,  $P=0.000$ ,  $0.002$ , and  $P=0.002$ , respectively). LSD test showed significant differences among sham group, and PTX and alendronate+PTX groups ( $P=0.000$  and  $P=0.002$ , respectively). All results were shown in Figure 3.

### Three point bending analysis

As shown in Figures 4, 5, 6 and 7 administration of PTX and alendronate alone and in combination did not significantly alter biomechanical properties of repairing complete osteotomy of femur compared with the control group.




**Figure 6.** Mean±SD of stress high load in the groups compared by the ANOVA and LSD tests. Groups: 1 (OVX, control), 2 (OVX, Sham), 3 (OVX, alendronate), 4 (OVX, PTX), and 5 (OVX, PTX and alendronate).

### Bending stiffness (N/mm)

The mean value of PTX group was higher than that of other groups. However the ANOVA evaluation for bending stiffness revealed no significant difference among the studied groups.

### Maximum force (N)

The mean value of Sham group was higher than other groups. However the ANOVA for maximum force



**Figure 7.** Mean±SD of energy absorption in the groups compared by the ANOVA and Lsd test. Groups: 1 (OVX, control), 2 (OVX, Sham), 3 (OVX, alendronate), 4 (OVX, PTX), and 5 (OVX, PTX and alendronate)

revealed no significant difference among the studied groups.

#### Stress high load (N/mm<sup>2</sup>)

The mean value of PTX was higher than that of other groups. However the ANOVA for stress high load revealed no significant difference among the studied groups.

#### Energy absorption (N mm)

The mean value of control was higher than that of other groups. However the ANOVA for energy absorption revealed no significant difference among the studied groups.

## Discussion

Fracture healing is a process in which injured bone recovers in both tissue formation and functional aspects. OP postpones the healing process and contributes to personal suffering and loss of activity. Osteoporotic patients are more prone to lose bone mass at the metaphyseal region which will then require treatment to improve bone mass. Therefore, it is important to investigate treatment with osteogenic potential and the capability to stimulate bone formation and to prevent bone loss [39]. Postmenopausal OP is the most common type of OP to affect women and lead to pathologic fracture. Estrogen Replacement Therapy (ERT), the recommended therapy for postmenopausal OP, is associated with higher risk of breast cancer, ovarian cancer and cardiovascular diseases [40]. According to the public health concern caused by

the burden of osteoporotic fractures, it is important that alternative treatment should now be thoroughly explored. Current drug therapy has been determined as inadequate to control incidence of OP and its complications such as fracturing [41]. Therefore, tests are being done for new anti-OP agents to provide more effective options than the current drugs used to control OP. PTX is used to manage vascular diseases such as ischemic heart disease and intermittent claudication. It improves peripheral blood flow by increasing erythrocyte exibility and vasodilatation. It also has an antitumor necrosis effect and may inhibit inflammatory reactions and decrease brosis [16]. Studies have shown that PTX has a positive effect administration on different complex skin wound healing models [42-45].

In the current study, we used a biomechanical measurement of the effect of PTX on bone fracture healing, which is essentially the ultimate proof of real alterations in bone repair-the strength of the healed bone [46]. Results of this current work show an increase in bending stiffness and stress high load mean values of repairing complete osteotomy in PTX-treated rats compared to control OVX-D. Results showed a trend toward effectiveness of PTX administration for improving biomechanical parameters of fracture callus in OVX-D. However, no significant difference was determined in the biomechanical parameters between PTX-treated rats and control OVX-D. It can be supposed that in the current study, PTX administration did not increase intracellular cAMP levels.

Bone strength is indirectly estimated by bone mineral density (BMD) by using Dual-Energy X-ray Absorptiometry (DXA). Considering DXA-measured BMD accounts for 60-70% of the variation in bone strength; in addition, the effects of anti-osteoporotic treatment and progression of osteoporosis were not captured by DXA. Geometry and trabecular microarchitecture should also be taken into account indeed. The assessment of the intrinsic mechanical quality of bony tissue should provide a better understanding regarding the role of tissue quality in determining bone strength [47,48].

Previous *in vitro* studies have shown that PTX promoted cellular and molecular pathways of bone formation. PTX promoted differentiation of osteogenic precursor cells toward an osteoblastic phenotype [49]. Consistent with these results are those reported in Rawadi *et al.*, showing a positive effect of PTX on osteoblastic differentiation *in vitro* by using two

mesenchymal cell lines, C3H10T1/2 and C2C12. These two mesenchymal cell lines were able to acquire the osteoblastic phenotype in the presence of bone morphogenetic protein-2 (BMP-2). Results determined that PTX induced the osteoblastic markers, osteocalcin and *Osf2/Cbfa1*, in these cells and enhanced BMP-2-induced expression of osteocalcin, *Osf2/Cbfa1*, and alkaline phosphatase [50]. McLeod *et al.*, reports on presence of radiation-induced fibrosis and suggests that the key event in development and progression of the condition is dysregulation of fibroblastic activity in irradiated areas, which not only damages atrophic tissue by damaging micro vessels but it allows for increased leakage of inflammatory mediators. The existence of inflammatory mediators such as TNF-alpha in the irradiated tissue then triggers further inflammatory response that causes more damage to local tissue. PTX has been found to act against some inflammatory mediators including TNF-alpha. However, Tocopherol is a methylated phenol compound with Vitamin E activity and is a scavenger of reactive oxygen species. McLeod *et al.*, reports that these two drugs in combination had a positive synergistic effect on the progression of fibrotic and inflammatory lesions that were caused by radiotherapy treatment [51].

Bisphosphonates have been recognized to have a positive effect on bone mineral density (BMD) and fracture incidence in osteoporotic bones. They are considered an effective, safe and are well tolerated; they can increase bone mass and reduce risk of fracture in primary and secondary OP [52]. Results of this study showed that alendronate-treated OVX-D did not reveal an increase in biomechanical parameters of repairing complete bone osteotomy compared to the control OVX rats. This observation is in accordance with results of a previous study [45]. Kolios *et al.*, investigated the prophylactic effects of estrogen and alendronate on rats with OP. After 10 weeks of OVX, standardized T-plate fixation and metaphyseal tibia osteotomy procedures were done. Tests determined that administration of estrogen significantly improved biomechanical properties and resistance to micro fracturing of callus compared to control and sham groups. Alendronate did not accelerate bone healing, which was shown by mechanical tests. Kolios *et al.*, concluded that osteoporotic metaphyseal fracture healing was qualitatively and quantitatively improved by estrogen prophylaxis [53].

The following hypothesis presents an explanation of the lack of stimulatory effect of the PTX administration

on osteoporotic rats that it could be due to inadequate or improper dosage. Vashghani Farahani *et al.*, assessed the effects of different dosages of PTX on biomechanical properties that take place during the late phase of the fracture healing process following a complete femoral osteotomy in a rat model. They divided 35 female rats into groups as follows; group 1 received PTX (50 mg/kg, once daily), starting 15 days before surgery, and group 2, group 3, and group 4 received 50, 100, and 200 mg/kg i.p. PTX, respectively, once daily after surgery. All animals received treatment for six weeks (until euthanized). Complete surgical transverse osteotomy procedure was performed in the right femur of each rat. At six weeks after surgery, femurs underwent a three-point bending test. It was determined that daily administration of 50 mg/kg PTX (groups 1 and 2) declined the high stress load in repairing osteotomized femur in comparison to the control group. The highest dose of PTX (200 mg/kg) significantly escalated high stress load in comparison to the control group, and groups 1, 2 and 3, per LSD findings. Vashghani Farahani *et al.*, concluded that treatment with 200 mg/kg PTX accelerated fracture healing compared with the control group [17].

## Conclusion

It was concluded that PTX administration with 200 mg/kg displayed no significant positive effect on biomechanical parameters of callus strength in OVX-D in the remodeling phase of complete femoral osteotomy. Further to this study it is suggested that different doses of PTX administration be tested on fracture in OP rats.

## Acknowledgments

We wish to extend our sincere thanks to the late Mrs. Jamileh Rezaei. This article had financially supported from the Research Department of Shahid Beheshti University of Medical Sciences, Tehran, Iran (grant no 1392-1-115-1159).

**Conflict of interests** The authors declare that there is no financial conflict of interests to publish these results.

## References

- Ozgediz D, Chu K, Ford N, Dubowitz G, Bedada AG, Azzie G, Gerstle JT, Riviello R. Surgery in global health delivery. *Mt Sinai J Med* 2011; 78(3): 327-341.

2. Mock C, Cherian MN. The global burden of musculoskeletal injuries: challenges and solutions. *Clin Orthop Relat Res* 2008; 466(10): 2306-2316.
3. Bandela V, Munagapati B, Karnati RK, Venkata GR, Nidudhur SR. Osteoporosis: Its Prosthodontic Considerations-A Review. *J Clin Diagn Res* 2015; 9(12): ZE01-4.
4. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. *Osteoporos Int* 2006; 17(12): 1726-1733.
5. Ray NF, Chan JK, Thamer M, Melton LJ 3rd. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. *J Bone Miner Res* 1997; 12(1): 24-35.
6. Tajeu GS, Delzell E, Smith W, Arora T, Curtis JR, Saag KG, Morrissey MA, Yun H, Kilgore ML. Death, debility, and destitution following hip fracture. *J Gerontol A Biol Sci Med Sci* 2014; 69(3): 346-353.
7. Pothiwala P, Evans EM, Chapman-Novakofski KM. Ethnic variation in risk for osteoporosis among women: a review of biological and behavioral factors. *J Womens Health (Larchmt)* 2006; 15(6): 709-719.
8. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. *Endocr Rev* 2000; 21(2): 115-137.
9. Ralston SH. Analysis of gene expression in human bone biopsies by polymerase chain reaction: evidence for enhanced cytokine expression in postmenopausal osteoporosis. *J Bone Miner Res* 1994; 9(6): 883-890.
10. Kinoshita T, Kobayashi S, Ebara S, Yoshimura Y, Horiuchi H, Tsutsumimoto T, Wakabayashi S, Takaoka K. Phosphodiesterase inhibitors, pentoxifylline and rolipram, increase bone mass mainly by promoting bone formation in normal mice. *Bone* 2000; 27(6): 811-817.
11. Ahlström M, Lamberg-Allardt C. Rapid protein kinase A-mediated activation of cyclic AMP-phosphodiesterase by parathyroid hormone in UMR-106 osteoblast-like cells. *J Bone Miner Res* 1997; 12(2): 172-178.
12. Ivitelli R, Bacskai BJ, Mahaut-Smith MP, Adams SR, Avioli LV, Tsien RY. Single-cell analysis of cyclic AMP response to parathyroid hormone in osteoblastic cells. *J Bone Miner Res* 1994; 9(9): 1407-1417.
13. Wronski TJ, Yen CF, Qi H, Dann LM. Parathyroid hormone is more effective than estrogen or bisphosphonates for restoration of lost bone mass in ovariectomized rats. *Endocrinology* 1993; 132(2): 823-831.
14. Degerman E, Smith CJ, Tornqvist H, Vasta V, Belfrage P, Manganiello VC. Evidence that insulin and isoprenaline activate the cGMP-inhibited low-Km cAMP phosphodiesterase in rat fat cells by phosphorylation. *Proc Natl Acad Sci U S A* 1990; 87(2): 533-537.
15. Marchmont RJ, Ayad SR, Houslay MD. Purification and properties of the insulin-stimulated cyclic AMP phosphodiesterase from rat liver plasma membranes. *Biochem J* 1981; 195(3): 645-652.
16. Bayat M, Amini A, Rezaie F, Bayat S. Patents of Pentoxifylline Administration on some diseases and chronic wounds. *Recent Patents on Regenerative Medicine* 2014; 4(2): 137-143.
17. Vashghani Farahani MM, Masteri Farahani R, Mostafavinia A, Abbasian MR, Pouriran R, Noruzian M, Ghoreishi SK, Aryan A, Bayat M. Effect of Pentoxifylline Administration on an Experimental Rat Model of Femur Fracture Healing With Intramedullary Fixation. *Iran Red Crescent Med J* 2015; 17(12): e29513.
18. Çakmak G, Pâhin MB, Özdemir BH, Karadeniz E. Effect of pentoxifylline on healing of segmental bone defects and angiogenesis. *Acta Orthop Traumatol Turc* 2015; 49(6): 676-682.
19. Atalay Y, Gunes N, Guner MD, Akpolat V, Celik MS, Guner R. Pentoxifylline and electromagnetic field improved bone fracture healing in rats. *Drug Des Devel Ther* 2015; 9: 5195-5201.
20. Bohn JC, Schussel JL, Stramandinoli-Zanicotti RT, Sassi LM. Tissue repair in osteoradionecrosis using pentoxifylline and tocopherol--report of three cases. *Oral Maxillofac Surg* 2016; 20(1): 97-101.
21. Erken HY, Burc H, Aydogan M. The Effect of Pentoxifylline on Spinal Fusion: An Experimental Study in Rabbits. *Spine (Phila Pa 1976)* 2014; 39(11): 27.
22. Labib GS, Farid RM. Osteogenic effect of locally applied Pentoxifylline gel: *in vitro* and *in vivo* evaluations. *Drug Deliv* 2015; 22(8): 1094-1102.
23. Queiroz-Junior CM, Bessoni RL, Costa VV, Souza DG, Teixeira MM, Silva TA. Preventive and therapeutic anti-TNF- $\alpha$  therapy with pentoxifylline decreases arthritis and the associated periodontal co-morbidity in mice. *Life Sci* 2013; 93(9-11): 423-428.
24. Aydin K, Sahin V, Gursu S, Mercan AS, Demir B, Yildirim T. Effect of pentoxifylline on fracture healing: an experimental study. *Ekleml Hastalik Cerrahisi* 2011; 22(3): 160-165.
25. Wei T, Sabsovich I, Guo TZ, Shi X, Zhao R, Li W, Geis C, Sommer C, Kingery WS, Clark DJ. Pentoxifylline attenuates nociceptive sensitization and cytokine expression in a tibia fracture rat model of complex regional pain syndrome. *Eur J Pain* 2009; 13(3): 253-262.
26. Horiuchi H, Saito N, Kinoshita T, Wakabayashi S, Tsutsumimoto T, Otsuru S, Takaoka K. Enhancement of recombinant human bone morphogenetic protein-2 (rhBMP-2)-induced new bone formation by concurrent treatment with parathyroid hormone and a phosphodiesterase inhibitor, pentoxifylline. *J Bone Miner Metab* 2004; 22(4): 329-334.
27. Bepe NS, Ozgüroğlu M, Kameroğlu K, Karahasanoglu T, Ober A. Pentoxifylline in the treatment of radiation-related pelvic insufficiency fractures of bone. *Radiat Med* 2003; 21(5): 223-227.
28. Robin JC, Ambrus JL. Study of antiosteoporotic agents in tissue culture. *J Med* 1984; 15(4): 319-322.
29. Robin JC, Ambrus JL. Studies on osteoporoses. XI. Effects of a methylxanthine derivative. A preliminary report. *J Med* 1983; 14(2): 137-145.
30. Magremanne M, Reychler H. Pentoxifylline and tocopherol in the treatment of yearly zoledronic acid-related osteonecrosis of the jaw in a corticosteroid-induced osteoporosis. *J Oral Maxillofac Surg* 2014; 72(2): 334-337.
31. Takami M, Cho ES, Lee SY, Kamijo R, Yim M. Phosphodiesterase inhibitors stimulate osteoclast formation via TRANCE/RANKL expression in osteoblasts: possible involvement of ERK and p38 MAPK pathways. *FEBS Lett* 2005; 579(3): 832-838.
32. Hosny KM. Alendronate sodium as enteric coated solid lipid nanoparticles; preparation, optimization, and *in vivo* evaluation to enhance its oral bioavailability. *PLoS One* 2016; 11(5): e0154926.
33. Imai K. Alendronate sodium hydrate (oral jelly) for the treatment of osteoporosis: review of a novel, easy to swallow formulation. *Clin Interv Aging* 2013; 8: 681-688.
34. Mostafavinia A, Ahadi R, Abdollahifar MA, Ghorishi SK, Jalalifirouzkouhi A, Bayat M. Evaluation of the Effects of Low-Level Laser Therapy on Biomechanical Properties and Hounsfield Unit of Partial Osteotomy Healing in an Experimental Rat Model of Type I Diabetes and Osteoporosis" under publication. DOI: 10.1089/pho.2016.4191.
35. Lee SW, Jeon TJ, Biswal S. Fracture Healing Effects of Locally-Administered Adipose Tissue-Derived Cells. *Yonsei Med J* 2015; 56(4): 1106-1113.
36. Little DG, Ramachandran M, Schindeler A. The anabolic and catabolic responses in bone repair. *J Bone Joint Surg Br* 2007; 89(4): 425-433.
37. Caro AC, Tucker JJ, Yannascoli SM, Dunkman AA, Thomas SJ, Soslowsky LJ. Efficacy of various analgesics on shoulder function and rotator cuff tendon-to-bone healing in a rat (*Rattus norvegicus*) model. *J Am Assoc Lab Anim Sci* 2014; 53(2): 185-192.
38. Freidouni M, Nejati H, Salimi M, Bayat M, Amini A, Noruzian M, Asgharie MA, Rezaian M. Evaluating glucocorticoid administration on biomechanical properties of rats' tibial

- diaphysis. *Iran Red Crescent Med J* 2015; 17(3): e19389.
39. Renno AC, de Moura FM, dos Santos NS, Tirico RP, Bossini PS, Parizotto NA. Effects of 830-nm laser, used in two doses, on biomechanical properties of osteopenic rat femora. *Photomed Laser Surg* 2006; 24(2): 202-206.
  40. Ibrahim N, Mohamed N, Shuid AN. Update on statins: hope for osteoporotic fracture healing treatment. *Curr Drug Targets* 2013; 14(13): 1524-1532.
  41. Lewiecki EM. New targets for intervention in the treatment of postmenopausal osteoporosis. *Nat Rev Rheumatol* 2011; 7(11): 631-638.
  42. Bayat M, Chelcheraghi F, Piryaei A, Rakhshan M, Mohseniefar Z, Rezaie F, Bayat M, Shemshadi H, Sadeghi Y. The effect of 30-day pretreatment with pentoxifylline on the survival of a random skin flap in the rat: an ultrastructural and biomechanical evaluation. *Med Sci Monit* 2006; 12(6): BR201-207.
  43. Velaie K, Bayat M, Torkman G, Rezaie F, Amini A, Noruzian M, Tavassol A, Bayat M. Evaluating the effects of pentoxifylline administration on experimental pressure sores in rats by biomechanical examinations. *Lab Anim Res* 2012; 28(3): 209-215.
  44. Babaei S, Bayat M, Nouruzian M, Bayat M. Pentoxifylline improves cutaneous wound healing in streptozotocin-induced diabetic rats. *Eur J Pharmacol* 2013; 700(1-3): 165-172.
  45. Babaei S, Bayat M. Pentoxifylline Accelerates Wound Healing Process by Modulating Gene Expression of MMP-1, MMP-3, and TIMP-1 in Normoglycemic Rats. *J Invest Surg* 2015; 28(4): 196-201.
  46. Luger EJ, Rochkind S, Wollman Y, Kogan G, Dekel S. Effect of low-power laser irradiation on the mechanical properties of bone fracture healing in rats. *Lasers Surg Med* 1998; 22(2): 97-102.
  47. Ammann P, Rizzoli R. Bone strength and its determinants. *Osteoporos Int* 2003; 14 Suppl 3: S13-18.
  48. Ammann P. [Determining factors of bone mechanical resistance]. *Therapie* 2003; 58(5): 403-407.
  49. Wakabayashi S, Tsutsumimoto T, Kawasaki S, Kinoshita T, Horiuchi H, Takaoka K. Involvement of phosphodiesterase isozymes in osteoblastic differentiation. *J Bone Miner Res* 2002; 17(2): 249-256.
  50. Rawadi G, Ferrer C, Spinella-Jaegle S, Roman-Roman S, Bouali Y, Baron R. 1-(5-oxohexyl)-3,7-Dimethylxanthine, a phosphodiesterase inhibitor, activates MAPK cascades and promotes osteoblast differentiation by a mechanism independent of PKA activation (pentoxifylline promotes osteoblast differentiation). *Endocrinology* 2001; 142(11): 4673-4682.
  51. McLeod NM, Pratt CA, Mellor TK, Brennan PA. Pentoxifylline and tocopherol in the management of patients with osteoradionecrosis, the Portsmouth experience. *Br J Oral Maxillofac Surg* 2012; 50(1): 41-44.
  52. Bilezikian JP. Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis. *Am J Med* 2009; 122(2 Suppl): S14-21.
  53. Kolios L, Hoerster AK, Sehmisch S, Malcherek MC, Rack T, Tezval M, Seidlova-Wuttke D, Wuttke W, Stuermer KM, Stuermer EK. Do estrogen and alendronate improve metaphyseal fracture healing when applied as osteoporosis prophylaxis? *Calcif Tissue Int* 2010; 86(1): 23-32.